Skip to content

Feasibility, acceptance, and effectiveness of mixed reality exposure therapy for patients with washing compulsions: a randomized controlled trial.

Feasibility, acceptance, and effectiveness of mixed reality exposure therapy for patients with washing compulsions: a randomized controlled trial. - MR-ERP-OCD

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
DRKS
Registry ID
DRKS00020969
Enrollment
64
Registered
2021-06-14
Start date
2022-02-10
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

F42.2

Interventions

Group 1: Interventional = Exposure therapy in mixed reality (MR) for the treatment of washing compulsions Group 2: Control group = Participation in self-guided exposures

Sponsors

Hamburgische Investitions- und Förderbank (IFB); Europäischer Fonds für regionale Entwicklung (EFRE)
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: - presence of OCD with washing compulsions (M.I.N.I. diagnosis) - the desire for treatment - no inpatient treatment (other outpatient treatment offers may be continued) - Gender: Both, male and female - Minimum Age: 18 Years - Maximum Age: 80 Years - consent to participate in exposures in MR or self-guided exposures as well as the all three assessments (informed consent) - ability to provide consent - sufficient understanding of the German language

Exclusion criteria

Exclusion criteria: - lifetime schizophrenia (F.20) or bipolar disorder - acute suicidal tendencies - mania - severe neuropsychological disease - current substance dependence

Design outcomes

Primary

MeasureTime frame
Yale-Brown Obsessive Compulsive Scale (Y-BOCS): The Y-BOCS is regarded as gold-standard for the assessment of OCD symptoms and symptom severity during the last week (baseline-, post after 6 weeks and follow-up after 3 months).

Secondary

MeasureTime frame
Sudden Units of Distress (SUD): Self-reported assessment of distress (before, during and after the exposure; session 3–6). Obsessive Compulsive Inventory- Revised (OCI-R): The OCI-R is a self-rating questionnaire that assesses OCD symptom severity during the last month (baseline-, post after 6 weeks and follow-up after 3 months). Obsessive-Beliefs-Questionnaire (OBQ): The OBQ is a self-rating questionnaire that assesses OCD relevant dysfunctional beliefs (baseline-, post after 6 weeks and follow-up after 3 months). Generalized Anxiety Disorder 7 (GAD-7): The GAD-7 is a self-rating questionnaire for the assessment of anxiety symptoms, which can be used as a screening instrument to identify a generalized anxiety disorder (baseline-, post after 6 weeks and follow-up after 3 months). Brief Experiential Avoidance Scale: The BEAQ is a self-rating questionnaire and assesses experiential avoidance, which describes the unwillingness to remain in contact with distressing emotions (baseline-, post after 6 weeks and follow-up after 3 months). Beck Depression Inventory-II (BDI-II): The BDI is a self-rating questionnaire to measure depressive symptoms over the past two weeks (baseline-, post after 6 weeks and follow-up after 3 months). Beliefs Questionnaire (BQ): A self-assessment questionnaire to assess dysfunctional beliefs (baseline-, post after 6 weeks and follow-up after 3 months). Quality of Life - Global item (WHO-QOL-BREF): Global item of the self-assessment questionnaire that measures quality of life (baseline-, post after 6 weeks and follow-up after 3 months). Questionnaire on attitudes towards exposure in MR: The questionnaire captures the previous, subjective attitude of patients towards exposure in mixed reality (baseline). Temple Presence Inventory (TPI): The TPI is a self-rating questionnaire to assess the sense of presence in MR (post after 6 weeks). Questionnaire on simultaneous treatments: The questionnaire on simultaneous treatments assesses if and

Countries

Germany

Contacts

Public ContactFranziska Miegel

Universitätsklinikum Hamburg-Eppendorf, Klinik und Poliklinik für Psychiatrie und Psychotherapie, Arbeitsgruppe Klinische Neuropsychologie

f.miegel@uke.de+49 40 7410 55868

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026